新型对映-贝壳杉烷二萜衍生物DS2抑制人胃癌细胞增殖与迁移
本研究探讨合成二萜类衍生物DS2对人胃癌细胞增殖与迁移的影响及机制。MTT、克隆形成、流式细胞术及划痕/Transwell实验显示,DS2以剂量依赖方式抑制MGC-803、SGC-7901和HGC-27增殖,对正常胃黏膜GES-1影响较小;在MGC-803中诱导G2/M阻滞和凋亡,抑制克隆形成与迁移,并上调E-cadherin、下调β-catenin和N-cadherin。
要点
- DS2剂量依赖性抑制胃癌细胞增殖,对正常胃黏膜细胞影响较小
- DS2诱导MGC-803细胞G2/M期阻滞和凋亡
- DS2抑制MGC-803迁移并上调E-cadherin、下调β-catenin和N-cadherin
核心结论
- 新化合物DS2具有强烈的抗胃癌活性,为设计合成更多更有效的二萜类抗肿瘤衍生物奠定基础。
研究设计与样本
- 体外研究,采用MTT法、平板克隆实验和流式细胞术检测DS2对胃癌细胞增殖、凋亡和周期的影响。
- 采用划痕实验和Transwell实验检测DS2对MGC-803迁移的抑制作用,Western blot检测迁移相关蛋白表达。
主要发现
- 6.25 μmol/L DS2作用24 h后,MGC-803、SGC-7901和HGC-27细胞生存率分别为(53.87±3.05)%、(55.91±6.97)%和(32.41±2.64)%。
- DS2对正常胃黏膜细胞GES-1影响不大,其生存率为(83.47±1.77)%。
- DS2将MGC-803细胞周期阻滞在G2/M期,并诱导其凋亡。
- DS2以剂量依赖方式抑制MGC-803单克隆形成及迁移能力。
- DS2作用于MGC-803后上调E-cadherin表达,下调β-catenin和N-cadherin蛋白表达。
临床怎么用
- DS2为胃癌体外模型中具有抗增殖和抗迁移活性的候选化合物,尚需进一步体内和临床研究验证。
局限性
- 研究仅基于体外细胞实验,未报告体内动物实验或临床数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the effects and the underlying mechanism of DS2, a newly synthetic analog of natural ent-kaurane diterpenoid, on the proliferation and migration capabilities of human gastric cancer cells. Methods: MTT assay, colony formation assay and flow cytometry were used to measure the effects of DS2 on growth, apoptosis and cell cycle of several human gastric cancer cell lines. The function of DS2 in the migration was further detected by wound healing and transwell assays. The expression of migration related proteins were determined by western blot. Results: DS2 inhibited the growth of MGC-803, SGC-7901 and HGC-27 cells in a dose dependent manner. After treatment of DS2 at a concentration of 6.25 μmol/L for 24 h, the survival rates of MGC-803, SGC-7901 and HGC-27 cells were 53.87±3.05%, 55.91±6.97% and 32.41±2.64%, respectively. However, for the normal gastric epithelial cell GES-1, no obvious growth inhibition was observed. In addition, DS2 caused significant G(2)/M arrest and induced apoptosis in MGC-803 cells. Furthermore, compared with the negative control, the colony formation, wound healing rate as well as the number of migrating cells of MGC-803 were significantly decreased in a dose dependent manner after DS2 treatment. DS2 induced the expression of E-cadherin, whereas β-catenin and N-cadherin levels were downregulated in MGC-803. Conclusion: The new compound DS2 has a strong anti-cancer activity, and this study will help us to design and synthesize better diterpenoids derivatives. 目的: 探讨合成的对映-贝壳杉烷型二萜类衍生物DS2抗胃癌细胞增殖及迁移的作用及其可能机制。 方法: 采用四甲基偶氮唑蓝法、平板克隆实验和流式细胞术检测DS2对胃癌细胞增殖的影响,采用划痕实验和Transwell实验检测DS2对胃癌细胞MGC-803迁移的抑制作用,采用Western blot检测DS2对细胞迁移相关蛋白表达的影响。 结果: DS2可抑制胃癌细胞增殖。6.25 μmol/L DS2作用MGC-803、SGC-7901和HGC-27胃癌细胞24 h后,细胞的生存率分别为(53.87±3.05)%、(55.91±6.97)%和(32.41±2.64)%;DS2对胃癌细胞的抑制活性呈剂量依赖性,而对正常胃黏膜细胞GES-1影响不大,其生存率为(83.47±1.77)%。DS2可将胃癌细胞MGC-803周期阻滞在G(2)/M期,同时诱导其凋亡,DS2以阻滞细胞周期和诱导凋亡的方式抑制胃癌细胞的生长增殖。DS2对MGC-803细胞的单克隆形成及迁移能力均有明显的抑制作用,并呈现剂量依赖性;DS2作用于MGC-803后可上调E-cadherin的表达,下调β-catenin和N-cadherin蛋白的表达。 结论: 新化合物DS2具有强烈的抗胃癌活性,为设计合成更多、更有效的二萜类抗肿瘤衍生物奠定基础。.
引用
- Zhu YL, Wang AF, Fan XX, et al. [DS2, a newly synthetic ent-kaurane diterpenoid analog, inhibits proliferation and migration of human gastric cancer cell]. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 30060356. doi:10.3760/cma.j.issn.0253-3766.2018.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。